Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
The global market for obesity drugs is soaring, yet Lilly has a dominant market share.
Overview
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are far and away the heavyweights in the global market for GLP-1 drugs, which effectively treat both type 2 diabetes and obesity.
And that market is exploding, particularly for obesity drugs. The global market for obesity medicines reached $66 billion in 2025. Bloomberg predicts it will hit $120 billion by 2030.
Details
Yet Lilly's share price is up 13.4% this year and 58% over the past 52 weeks, while Novo Nordisk shares are up just 0.4% this year and down 5% over the past 52 weeks. Since July 2024, Novo has plummeted 62%.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.